BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (1986) 59, 1185-1194
© 1986 British Institute of Radiology
doi:
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merrick, M. V.
Right arrow Articles by Merrick, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merrick, M. V.
Right arrow Articles by Merrick, J. M.

The British Journal of Radiology, Vol 59, Issue 708 1185-1194, Copyright © 1986 by British Institute of Radiology

ARTICLES

Bone scintigraphy in lung cancer: a reappraisal

MV Merrick and JM Merrick

The prognostic significance of bone scintigraphy was investigated by following 587 consecutive patients with lung cancer, in whom this investigation had been performed, for up to 9 years, or until death. Survival was unrelated to age, sex or cell type. However, pain and abnormal bone scintigraphy were both independently associated with a significantly reduced survival compared with those who were free of pain or who had normal bone scintigraphy. These factors were cumulative. The association remained equally valid for all cell types. Claims that a single metastasis is not prognostically significant are unfounded. It is suggested that the results of some chemotherapy trials must be reconsidered in the light of present findings, because of the lack of adequate control groups; the results could be construed to show a beneficial effect only in patients with bone metastases and a poor prognosis, but little or no effect in patients with normal bone scintigraphy. As judged by clinical and radiological follow-up and post-mortem examination, skeletal scintigraphy in patients with lung cancer had a sensitivity of 0.89, a non-specificity (false positives/true negatives) of 0.00 and an accuracy of 0.78. With existing radiopharmaceuticals there is an irreducible residue of false negatives due to deposits which provoke little or no osteoblastic response. Bone scintigraphy is, thus, indicated in any patient with lung cancer with unexplained symptoms and whenever staging is required, because of the prognostic implications. It should precede other staging investigations because the high detection rate may render other tests unnecessary.


This article has been cited by other articles:


Home page
 ChestHome page
S. Erturan, M. Yaman, G. Aydin, I. Uzel, B. Musellim, and K. Kaynak
The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-small Cell Lung Cancer
Chest, February 1, 2005; 127(2): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. H. Guyatt, D. J. Cook, L. E. Griffith, J. D. Miller, T. R.J. Todd, M. R. Johnston, T. L. Winton, A. G. Casson, R. I. Inculet, G. E. Darling, et al.
Surgeons’ assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer
Ann. Thorac. Surg., August 1, 1999; 68(2): 309 - 315.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 1986 by the British Institute of Radiology.